XERS vs. UAMY
XERS (Xeris Biopharma Holdings, Inc.) and UAMY (United States Antimony Corporation) are both stocks. XERS operates in Biotechnology (Healthcare), while UAMY operates in Other Industrial Metals & Mining (Basic Materials). Over the past 5 years, XERS returned 10.76%/yr vs 49.62%/yr for UAMY. At a 0.13 correlation, their price movements are largely independent.
Performance
XERS vs. UAMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XERS achieves a -8.28% return, which is significantly lower than UAMY's 39.64% return.
XERS
- 1D
- 4.35%
- 1M
- 16.32%
- YTD
- -8.28%
- 6M
- -1.10%
- 1Y
- 55.17%
- 3Y*
- 34.94%
- 5Y*
- 10.76%
- 10Y*
- —
UAMY
- 1D
- -10.13%
- 1M
- -16.75%
- YTD
- 39.64%
- 6M
- 16.25%
- 1Y
- 157.72%
- 3Y*
- 182.66%
- 5Y*
- 49.62%
- 10Y*
- 40.73%
XERS vs. UAMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
XERS Xeris Biopharma Holdings, Inc. | -8.28% | 131.56% | 44.26% | 76.69% | -54.61% | -40.45% | -30.21% | -58.53% | 7.94% |
UAMY United States Antimony Corporation | 39.64% | 183.62% | 610.84% | -48.86% | -2.19% | -4.64% | 35.58% | -33.62% | 12.62% |
Correlation
The correlation between XERS and UAMY is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Jun 21, 2018 | 0.13 |
The correlation between XERS and UAMY shifts across timeframes, from 0.03 (1 year) to 0.15 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
XERS:
$1.28B
UAMY:
$992.70M
XERS:
$0.07
UAMY:
-$0.13
XERS:
3.95
UAMY:
23.16
XERS:
98.30
UAMY:
7.53
XERS:
$314.85M
UAMY:
$39.04M
XERS:
$187.04M
UAMY:
$4.34M
XERS:
$41.72M
UAMY:
-$15.23M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XERS vs. UAMY — Risk / Return Rank
XERS
UAMY
XERS vs. UAMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and United States Antimony Corporation (UAMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XERS | UAMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.20 | ||
| Sortino ratioReturn per unit of downside risk | -0.61 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.25 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.19 | 2.14 | -0.95 |
| Martin ratioReturn relative to average drawdown | 2.08 | 3.61 | -1.53 |
Loading charts...
Drawdowns
XERS vs. UAMY - Drawdown Comparison
The maximum XERS drawdown since its inception was -96.22%, roughly equal to the maximum UAMY drawdown of -96.44%. Use the drawdown chart below to compare losses from any high point for XERS and UAMY.
Loading charts...
Drawdown Indicators
| XERS | UAMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.22% | -96.44% | +0.22% |
Max Drawdown (1Y)Largest decline over 1 year | -46.57% | -74.30% | +27.73% |
Max Drawdown (3Y)Largest decline over 3 years | -49.83% | -74.30% | +24.47% |
Max Drawdown (5Y)Largest decline over 5 years | -78.59% | -80.46% | +1.87% |
Max Drawdown (10Y)Largest decline over 10 years | — | -89.76% | — |
Current DrawdownCurrent decline from peak | -73.56% | -59.87% | -13.69% |
Average DrawdownAverage peak-to-trough decline | -78.99% | -66.40% | -12.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.61% | 43.94% | -17.33% |
Volatility
XERS vs. UAMY - Volatility Comparison
The current volatility for Xeris Biopharma Holdings, Inc. (XERS) is 10.32%, while United States Antimony Corporation (UAMY) has a volatility of 29.25%. This indicates that XERS experiences smaller price fluctuations and is considered to be less risky than UAMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XERS | UAMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.32% | 29.25% | -18.93% |
Volatility (6M)Calculated over the trailing 6-month period | 33.46% | 92.81% | -59.35% |
Volatility (1Y)Calculated over the trailing 1-year period | 55.68% | 132.57% | -76.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 68.45% | 95.28% | -26.83% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.61% | 101.14% | -21.53% |
Dividends
XERS vs. UAMY - Dividend Comparison
Neither XERS nor UAMY has paid dividends to shareholders.
Financials
XERS vs. UAMY - Financials Comparison
This section allows you to compare key financial metrics between Xeris Biopharma Holdings, Inc. and United States Antimony Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
XERS and UAMY have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
UAMY has higher volatility (29.25%) compared to XERS (10.32%). In terms of maximum drawdown, XERS dropped -96.22% vs UAMY's -96.44%.
UAMY currently has the higher Sharpe Ratio (1.20 vs 1.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XERS and UAMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer